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Abstract
Background: The body mass index (BMI) is the most commonly used marker for evaluating obesity related risks, 
however, central obesity measures have been proposed to be more informative. Lipid accumulation product (LAP) is 
an alternative continuous index of lipid accumulation, which is computed from waist circumference (WC, cm) and 
triglycerides (TGs, mmol/l): (WC-65) ×TG (men) and (WC-58) ×TG (women). We sought in this study to assess if LAP can 
outperform BMI, waist-to-height-ratio (WHtR), or waist-to-hip-ratio (WHpR) in identifying prevalent and predicting 
incident diabetes.
Results: The cross-sectional analyses were performed on a sample included 3,682 men and 4,989 women who were 
not pregnant, aged ≥ 20 years. According to the age (≥ 50 and <50 years) - and sex-specific analyses, odds ratios (ORs) 
of LAP for prevalent diabetes were higher than those of BMI, WHpR, or WHtR among women, after adjustment for 
mean arterial pressure and family history of diabetes. The OR of LAP in old men was lower than those of other adiposity 
measures; in young men, however, LAP was superior to BMI but identical to WHpR and WHtR in identifying prevalent 
diabetes. Except in young men, LAP showed highest area under the receiver operating characteristic curves (AROC) for 
prevalent diabetes (P for trend ≤ 0.005).
For longitudinal analyses, a total of 5,018 non-diabetic subjects were followed for ~6 years. The ORs of BMI, WHpR,
and WHtR were the same as those of LAP in both sexes and across age groups; except in young men where LAP was
superior to the BMI. AROCs of LAP were relatively the same as anthropometric adiposity measures.
Conclusions: LAP was a strong predictor of diabetes and in young individuals had better predictability than did BMI; it 
was, however, similar to WHpR and WHtR in prediction of incident diabetes.
Background
There is an emerging view that type 2 diabetes (hereafter
diabetes) may reflect not so much as an isolated impair-
ment of glucose regulation, rather the complex metabolic
consequences of accumulating ectopic lipids or hepatic
fat [1-4]. Obesity is commonly used to imply excess fat,
but it is ordinarily classified according to excess weight.
This semantic inconsistency may help to explain why the
body mass index (BMI) performs only modestly as a pre-
dictor of medical risk [5].
Lipid accumulation should be defined and measured
specifically in those contexts where accumulation may
represent a physiologic danger [6,7]. These contexts
might be described as lipid over accumulation [8]. Attrib-
uting culpability to components of adipose or lean tissue
should also be avoided; since although enlarged, they
might enhance physiologic processes or reduce the risk of
disease.
Kahn described a simple index for estimating lipid over
accumulation among adults - designated the "lipid accu-
mulation product" (LAP) - based on a combination of two
measurements that are safe and inexpensive to obtain.
One is waist circumference (WC), a measure of truncal
fat that includes the visceral (intra-abdominal) depot.
The other is the fasting concentration of circulating trig-
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lycerides (TGs). The simple index described there was
developed to express a continuous risk function. If LAP is
better correlated than BMI with cardiovascular risk fac-
tors, this finding would support the notion that the over
accumulation of lipid carries worse cardiovascular conse-
quences than the less specific over accumulation of
weight [9].
In a population based cross sectional study LAP has
been shown to be better than BMI in identifying preva-
lent diabetes [1]. The BMI can neither distinguish
between fat and lean tissues nor identify the anatomic
location or function of distinct fat depots. But abdominal
adiposity has been shown to be more closely linked with
adverse metabolic consequences and has been suggested
to precede insulin resistance [9].
An unanswered question in original description of LAP
was if LAP could be a strong predictive of diabetes. Less
is known concerning the performance of LAP as com-
pared to the measures of abdominal adiposity. Our pri-
mary focus in this study, therefore, was to assess if LAP
can outperform BMI, waist-to-height ratio (WHtR), or
waist-to-hip ratio (WHpR) in identifying prevalent- or
predicting incident-diabetes.
Methods
Study design and population
Between 1999 and 2001 the Tehran Lipid and Glucose
Study (TLGS) recruited a population-based cohort of
more than 15,000 residents aged over 3 years from dis-
trict 13 of Tehran, as a representative of Tehran popula-
tion to participate in a baseline study, of whom 10,368
aged ≥ 20 years. The rationale and design of the study has
been described elsewhere [10].
For longitudinal analyses, we excluded individuals
assigned to the intervention study (n = 3,931), those with
prevalent diabetes mellitus (using oral hypoglycemic
agents or insulin, baseline fasting plasma glucose (FPG) ≥
7.0 mmol/l or 2 hour post challenge plasma glucose (2h-
PCPG) ≥ 11.1 mmol/l, n = 698), and those with incom-
plete data on their diabetes status (n = 623) or baseline
clinical measurements (n = 98). The remaining 5,018
non-diabetic subjects were followed up to the second
(2002-2005) and third (2005-2008) TLGS examinations
(end point for these analyses), ~3 years apart, for an aver-
age period of ~6 years (Figure 1). The screening method
used at the baseline as well as the follow-up visits was the
same and included measurements of both FPG and 2h-
PCPG. Participants who left the study before the end
point for the longitudinal analyses or before first develop-
ing diabetes were excluded. The final sample for longitu-
dinal analyses consisted of 3,242 participant. The main
reasons for lack of attendance at follow-up examinations,
despite repeated calls, were either migration or other per-
sonal reasons. Informed written consent was obtained
from all subjects and the Ethical Committee of Research
Institute for Endocrine Sciences approved this study.
The cross sectional analyses was performed on a sam-
ple included 3682 men and 4989 women, aged 20 years
and over, who were not pregnant, with all relevant data
available (Figure 1).
Clinical, anthropometric, and laboratory measurements
The baseline examination obtained information on family
history of diabetes and medication use. The standard 2
hour post-challenge plasma glucose (2h-PCPG) test was
performed for all individuals ≥ 20 years, not on glucose
lowering drugs. Height, weight, WC, plasma glucose
level, and serum triglycerides (TGs) levels were measured
using previously reported methods [11]. BMI was calcu-
lated as weight in kilograms divided by height in meters
squared. WHpR was calculated as waist circumference
(WC) divided by hip circumference and WHtR was cal-
culated as WC divided by height.
Definition of variables and outcomes
Positive family history of diabetes was defined as having
at least one parent or sibling with diabetes. Participants
were classified as having developed new diabetes during
follow-up if they met at least one of these criteria: FPG ≥
7 mmol/l, or 2h-PCPG ≥ 11.1 mmol/l or taking anti-dia-
betic medication. Impaired fasting plasma (IFG) and
Impaired glucose tolerance (IGT) were defined as FPG
Figure 1 Study population: included, excluded, lost to the follow-
up and events, and censored individuals. Starting point is black 
text-box with upward, for cross sectional study; downward, for longi-
tudinal study.
Phase 1 (1999-2001): 10368 aged  20 years  
Eligible subjects: 5018 non-diabetic individuals aged  20 
Phase 2 (2002-2005): 2937 non-diabetic individuals aged  20 
67 Diabetic 
individuals
2270 Non-diabetic 
individuals
479 Lost to follow-up 
43 Diabetic 
individuals
741 Non-diabetic 
individuals
1297 Lost to follow-up
121 diabetic individuals 
Intervention group( n=3931)
Prevalent diabetes (n=698)
Missing data (n=721) 
2337 attended phase 2  784 did not attend phase 2 
Phase 3 (2005-2008): 3121 non-diabetic individuals aged  20 
Missing data (n=1617) 
Cross sectional study (n=8671)
Pregnant (n=80) Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
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from 5.6-6.9 mmol/l and 2h-PCPG from 7.8-11.0 mmol/l,
respectively [12]. The LAP was defined to, theoretically,
describe the extent to which an individual had travelled
the route of both increasing waist and increasing TG [9]:
Mean arterial pressure (MAP) was calculated as:
Statistical analysis
All mean are presented as mean (standard deviation).
The mean values and the proportions of baseline vari-
ables across quartiles of LAP were compared, in each sex,
using the linear and logistic regression model, respec-
tively. To identify whether LAP performs better than the
anthropometric variables, i.e. BMI, WHpR, or WHtR for
identifying elevated FPG, 2h-PCPG, the linear regression
model was applied. Sex- and age-specific (20-49, ≥ 50
years) estimates of FPG and 2h-PCPG based on LAP,
BMI, WHpR, or WHtR, were derived from linear regres-
sion models. Baseline variables (LAP, BMI, WHpR,
WHtR, FPG, and 2h-PCPG) were loge-transformed
before standardization to improve discrimination and
calibration of the models and to minimize the effect of
extreme observations [13]. The correlation coefficient (R)
represents the linear relationship between two continu-
ous variables. The squared correlation coefficient (R2),
generally known as the coefficient of determination, rep-
resents the proportion of common variation in the two
variables i.e. the strength or magnitude of the relation-
ship. The LAP and BMI, WHpR and WHtR were com-
pared in regards of the proportion of the total variation in
FPG and 2h-PCPG, that each index could explain, which
is R2 for each regression model. Logistic regression was
used to assess contribution of each risk factor to the risk
of prevalent diabetes IFG, IGT and incident diabetes.
Wald tests of the linear hypotheses concerning the logis-
tic regression models coefficients (paired homogeneity
test) were performed to test the null hypotheses that the
odds ratios (ORs) (effect size) for LAP were equal to
those for BMI, WHpR, or WHtR. As the anthropometric
measurements were highly correlated, the ORs obtained
from logistic regression models including more than one
measure were difficult to interpret because of collinearity.
Because BMI, WHpR, WHtR, and LAP were highly cor-
related, we assessed collinearity between these variables
using condition indices and variance inflation factor
(VIF). Condition indices >30 or VIFs >10 warrant caution
[14]. Effort was made to reduce collinearity by modeling
variables in quartiles and standardizing the loge-trans-
formed variables. Receiver operating characteristic
(ROC) curve analysis [15] was used to determine, in com-
bination with family history of diabetes, and MAP,
whether LAP would better discriminate incident diabetes
cases than did other anthropometric variables. The area
under the ROC curve (AROC) from the prediction of
multivariate-adjusted LAP was compared with the
AROCs from the prediction of multivariate-adjusted
models including anthropometric variables (each investi-
gated one at a time). The AROCs were compared accord-
ing to the method suggested by DeLong [16]. We
reported P value without adjusting for pairwise multiple
comparisons. Reporting such a P value will allow each
reader to decide whether the reported differences are
important or not [17,18].
Results
A total of 8,671 and 3,242 participants, with 42.8% and
42.2% being male, included in the cross sectional and lon-
gitudinal study, respectively. Mean age of the subjects was
42.9 ± 15.0 and 41.6 ± 13.2 in cross sectional and pro-
spective study respectively.
Table 1 represents baseline characteristics across LAP
q u a r t i l e s  b y  s e x e s .  C u t - p o i n t s  f o r  LA P  w e r e  h i g h e r  i n
women than in men. In both sexes the prevalence of fam-
ily history of diabetes, diabetes, IFG, and IGT as well as
mean levels of systolic and diastolic blood pressure, MAP,
WHpR, WHtR, BMI, age, FPG, and 2 h-PCGP at the time
of the LAP measurement progressively increased across
LAP quartiles.
Baseline and future plasma glucose levels prediction
As shown in Tables 2, LAP had almost consistently stron-
ger association (higher R2) with baseline and future levels
of FPG and 2h-PCPG than did BMI. In women and old
men, the LAP explained greater variability in the baseline
levels of FPG and 2h-PCPG than did WHpR and WHtR.
In young men, however, the amount of variability in the
baseline levels of FPG and 2h-PCPG explained by WHpR
was higher than those of other predictors. The variations
in the future levels of FPG were best explained by LAP in
young men and women. Among older men and women,
the variations in the future levels of FPG were best
explained by BMI and WHtR, respectively. In young
women, the variations in the future levels of 2h-PCPG
were best explained by WHtR. In younger participants,
the variations in the baseline and future levels of FPG and
2h-PCPG were generally better explained by baseline
LAP, BMI, WHpR, and WHtR than it were in older ones.
Excluding older men, the LAP consistently explained
more variations either in baseline or in future levels of
LAP for men WC cm 65 TG concentration mmol L
LAP for 
= [] − () × [] () /
w women WC cm 58 TG concentration  mmol L = [] − () × [] () /
MAP 2 diastolic blood pressure systolic blood pressure 3 =× + () /Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
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FPG and 2h-PCPG than did BMI. LAP, however, ranked
differently in relation to WHpR or WHtR, with no uni-
form pattern being observed.
Diabetic status
As is depicted in figure 2, LAP was superior to BMI in
identifying prevalent diabetes (P < 0.001); but not much
so as compared to WHpR (P = 0.015) and WHtR (P =
0.014), considering the multiplicity of inference. Odds
ratios (4th vs. 1st quartile) of LAP for IGT, IFG and inci-
dent diabetes were greater than those of BMI (Ps < 0.001),
again LAP was found to be similar to WHpR (PIGT =
0.273, PIFG = 0.072, and PIncident diabetes = 0.220) and WHtR
(PIGT = 0.563, PIFG = 0.470, and PIncident diabetes = 0.971).
The odds ratios for IGT, IFG, prevalent and incident
diabetes corresponding to a 1 standard deviation incre-
ment in the baseline levels (log-scale) of LAP, BMI,
WHpR, and WHtR estimated separately for each variable
are presented in Table 3 and 4. The paired homogeneity
Table 1: Baseline characteristics of participants in longitudinal study.
Variable Q1 LAP Q2 LAP Q3 LAP Q4 LAP P for trend
Men
LAP 0.62-21.96 21.97-40.93 40.94-68.51 68.52-570.26
Age 33.1(15.4) 43.3(13.5) 45.0(13.3) 44.7(12.6) <0.001
FHx of DM 67(20.1) 75(22.5) 94(28.2) 97(29.1) = 0.002
DM 8(9.1) 13(14.8) 29(33.0) 38(43.2) <0.001
IFG 19(9.) 747(24.0) 48(24.5) 82(41.8) <0.001
IGT 14(0.9) 34(21.9) 44(28.4) 63(40.6) <0.001
SBP 114.3(16.6) 117.3(14.9) 122.6(18.4) 124.7(16.6) <0.001
DBP 73.3(9.8) 76.8(9.3) 80.4(10.4) 82.1(10.1) <0.001
MAP 87.3(10.7) 90.4(10.2) 94.4(12.0) 96.3(11.2) <0.001
BMI 21.6(2.4) 25.0(2.3) 27.1(2.7) 29.0(3.4) <0.001
WHpR 84.0(4.8) 90.3(4.7) 94.3(5.0) 96.7(5.1) <0.001
WHtR 44.5(4.1) 50.1(3.9) 54.6(4.2) 57.7(5.1) <0.001
FPG 4.9(0.5) 5.1(0.5) 5.1(0.5) 5.2(0.6) <0.001
2h-PCPG 5.0(1.4) 5.6(1.6) 5.9(1.7) 6.2(1.8) <0.001
Women
LAP 0.56-22.26 22.27-42.90 42.91-73.98 73.99-620.39
Age 31.2(8.5) 39.6(11.5) 43.9(11.9) 50.0(11.1) <0.001
FHx of DM 103(19.4) 135(25.4) 140(26.4) 153(28.8) <0.001
DM 5(3.5) 19(13.3) 48(33.6) 71(49.7) <0.001
IFG 14(6.20) 43(19.1) 72(32.0) 96(42.7) <0.001
IGT 14(5.1) 42(15.2) 86(31.2) 134(48.6) <0.001
SBP 106.8(10.9) 114.3(16.1) 120.2(16.7) 125.7(19.3) <0.001
DBP 71.3(8.2) 76.4(9.5) 79.3(9.4) 82.2(9.5) <0.001
MAP 83.1(8.2) 89.0(10.8) 92.9(10.8) 96.7(11.9) <0.001
BMI 23.0(3.2) 26.8(3.4) 29.2(3.7) 31.5(4.3) <0.001
WHpR 75.6(5.1) 81.8(6.2) 86.1(6.1) 89.5(6.5) <0.001
WHtR 46.4(4.5) 53.8(5.2) 58.8(5.3) 63.5(6.2) <0.001
FPG 4.7(0.4) 4.9(0.5) 5.1(0.5) 5.2(0.6) <0.001
2h-PCPG 5.2(1.2) 5.9(1.4) 6.4(1.5) 6.9(1.6) <0.001
All continuous variables are represented as mean (SD) and all dichotomous variables as number (percent). P values for trends were obtained 
from linear or logistic regression models for continuously- and binary-distributed variables, respectively.
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; FHx, family history; PFG, fasting plasma glucose; IFG, impaired 
fasting glucose; IGT, impaired glucose tolerance; LAP, lipid accumulation product; MAP, mean arterial pressure; Q, quartile; SBP, systolic blood 
pressure; 2 h-PCGP, 2-hour post challenge plasma glucose; WHpR waist to hip ratio; WHtR, waist to height ratio.Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
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test adjusted for baseline MAP and family history of dia-
betes indicated that odds ratios (size of risk) of LAP for
incident diabetes did not differ from those for WHpR or
WHtR. All condition indices were smaller than 5 and all
VIFs were smaller than 4.
The difference in discriminatory capacity of the predic-
tive age- and sex-specific models incorporating family
history of diabetes, MAP, and either LAP, BMI, WHpR, or
WHtR is presented in Table 3 and 4. AROCs obtained
from competing models for identifying prevalent diabe-
tes, IFG, and IGT and also incident diabetes. The dis-
criminatory capacities in older participants were lower
than in younger ones. LAP was, generally, superior to
anthropometric variables in discriminating prevalent dia-
betes, IFG, and IGT. The discriminatory capacity of LAP
for incident diabetes, however, was similar to those of
BMI, WHpR, and WHtR.
Discussion
Using data from a population based study, we extended
the superiority in identifying prevalent diabetes of LAP
over BMI, reported by Kahn [1], and showed that LAP
had higher ORs for prevalent diabetes than did WHpR
and WHtR; this superiority, however, was not observed in
all subgroups. For different outcomes (IFG, IGT, preva-
lent or incident diabetes), no clinically significant differ-
ence was observed between discriminatory capacities of
LAP, BMI, WHpR, or WHtR. WHtR, WHpR, and BMI
showed as strong associations with incident diabetes as
did LAP , except in young men. W e observed that LAP
was superior to BMI, and approximately equal to WHtR
and WHpR for predicting FPG and 2h-PCPG levels.
The effect of LAP and other measures of adiposity on
plasma glucose levels and prevalent and incident diabetes
were moderated by age and sex, the finding that was also
Table 2: Percentages of the variation* (adjusted R2) in 2h-PCPG and FPG explained by LAP, BMI, WHtR, and WHpR.
FPG 2h-PCPG
Cross-sectional Longitudinal Cross-sectional Longitudinal
Male
20-49
LAP 5.8 8.40 10.1 7.80
BMI 3.6 6.90 5.7 5.40
WHpR 5.9 7.10 11.5 8.60
WHtR 5.3 8.30 10.2 8.60
≥ 50
LAP 5.6 2.20 8.8 5.00
BMI 3.2 2.70 4.9 6.00
WHpR 3.2 2.20 6.3 8.00
W H t R 3 . 62 . 1 06 . 5 1 0 . 2 0
Female
20-49
LAP 10.2 7.80 17.3 10.40
BMI 6.9 5.10 9.8 5.80
WHpR 6.8 5.00 10.5 6.00
WHtR 9.3 6.10 13.6 7.40
≥ 50
LAP 7.2 3.50 8.5 7.30
BMI 2.4 3.10 1.2 3.80
WHpR 3.6 3.70 5.1 7.10
WHtR 4.6 4.70 4.9 9.00
*Values were obtained from models adjusted for age. LAP, BMI, WHpR and WHtR were all evaluated in log-scale.
BMI, body mass index; FPG, Fasting plasma glucose; LAP, lipid accumulation product; 2h-PCPG, 2 hour post challenge plasma glucose; WHpR, 
waist to hip ratio; WHtR, waist to height ratio.Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
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reported by previous studies [19]. It has been demon-
strated that the variation in visceral adipose tissue accu-
mulation can explain a significant proportion of the sex-
as well as age-related differences in the metabolic risk
profile [20]. Assessing risk in older patients is challenging
since traditional risk factors are less predictive in older
versus middle-age populations. Evidence suggests that
obesity in the elderly may not be associated with the same
risks as in younger individuals, and in certain aspects, can
even be protective [21]. Age-dependent weight loss in
later life with stable or increasing adiposity is character-
ized by a redistribution of the fat mass that favors
enhanced visceral and ectopic adipose tissue accumula-
tion [22]. Older individuals are generally shorter than
younger individuals because of shrinkage of the spine due
to vertebral bone loss, kyphosis, and scoliosis. The BMI
of older individuals, hence, may be overestimated [23]. In
the Rosetta Study, however, older adults had, on average,
more fat than younger adults at any given BMI [24]. The
distribution of body fat changes with age and relatively
more fat accumulates in the abdomen and less fat at the
extremities [25]. For a given WC, visceral fat has been
shown to be higher in older individuals compared with
younger individuals [26], suggesting that absolute levels
of WC should be interpreted differently in younger and
older persons. We hypothesized that the aging modifies
the association of the anthropometric measures of adi-
posity and LAP with visceral and ectopic adipose tissue
accumulation, which are thought of as mediators of the
effect of adiposity on FPG or 2h-PCPG. Decreased insu-
lin sensitivity at the cellular level is also a natural conse-
quence of aging [22] that can, independent of adiposity,
subject the elderly population to the higher risk of devel-
oping diabetes; and therefore affect the association of
measures of adiposity with diabetes.
Different modalities have been used to characterize the
relationship between visceral fat and diabetes. Imaging
techniques that directly quantify the visceral adipose tis-
sue and subcutaneous adipose tissue are costly and inva-
sive; therefore, anthropometric measurements are more
commonly utilized. LAP , has been reported to offer an
inexpensive and non invasive tool to estimate total body
lipid accumulation in comparison with sophisticated
imaging methods for estimating the lipid burden or
uptake in isolated tissues [1]. We observed, however, that
if LAP is to be used for predicting diabetes, it might not
be superior to WHtR or WHpR. The quantity of intra-
abdominal fat being strongly related to the metabolic dis-
orders is the basis for suggestions regarding the superior-
ity of anthropometric measures that describe central fat
distribution to general measures of obesity, with respect
to the prediction of diabetes. Previous studies and most
recently Kahn et al. have shown that height is an indepen-
dent predictor of diabetes [2,27,28]. Hip circumference
has  a lso  bee n pr evious l y r epo rt ed t o be  indepe nde n t l y
and inversely associated with diabetes [29]. So the WHpR
and WHtR may represent joint risk related to WC and
hip and height, respectively. We have previously shown
that WHtR is superior to the other anthropometric mea-
sures of obesity in predicting diabetes [30]. Anthropo-
metric measures of central adiposity and general obesity
rank variably in predicting diabetes in different ethnic
populations [31]. Some studies recently compared differ-
ent anthropometric measures in terms of their ability to
predict diabetes and to determine whether predictive
ability was modified by ethnicity. They observed that
measures of central and overall adiposity predicted diabe-
tes to a similar degree except for slight superiority for
WHtR [32-34].
We have previously shown, in a cross sectional study,
that TGs is independently associated with undiagnosed
diabetes [35]. In the current study LAP was shown to be
better at identifying prevalent diabetes than at predicting
incident diabetes. This means that by the time one would
expect the LAP to be elevated the elevated glucose levels
might have been already attained; the finding that sup-
ports the view that diabetes is not merely impairment in
glucose regulation, rather the complex metabolic conse-
quences of accumulating ectopic lipids or hepatic fat [1-
4].
We observed that anthropometric measures of adipos-
ity as well as LAP explained more variations in 2h-PCPG
levels than in FPG levels. The release of free fatty acids
from visceral fat into the portal vein that directly leads to
the liver may cause reduced hepatic insulin clearance,
Figure 2 Fourth vs. first quartiles of LAP versus BMI, WHpR, and 
WHtR, for identification of prevalent DM, IFG, and IGT, and pre-
diction of incident DM. BMI, body mass index; DM, diabetes mellitus; 
IFG, impaired fasting plasma glucose; IGT, impaired glucose tolerance; 
LAP, lipid accumulation product; WHpR, waist to hip ratio; WHtR, waist 
to height ratio.Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
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increased gluconeogenesis and increased dyslipidaemia
[23] that manifests as increased 2h-PCPG. Aging and
genetic predisposition (for which we were not able to
control) contribute to β-cell dysfunction; the chronic glu-
cotoxic and lipotoxic effects on FPG of the insulin-resis-
tant state in obesity, might have been confounded by the
genetic factor(s) [22].
The LAP, WHpR, and WHpR being more strongly asso-
ciated with 2h-PCPG than with FPG, can potentially
make them practical tools to be used for selecting those
with normal FPG levels in whom testing 2h-PCPG may
be of benefit. Our findings indicate that the predictive
value of the LAP and WHpR or WHtR were similar. The
message is important since WHpR and WHtR are easier
to measure than is LAP; a major obstacle for many people
could be the requirement of a venipuncture to obtain TGs
levels in a fasting state for obtaining LAP levels [9].
Table 3: Prediction of IFG and IGT by LAP, BMI, WHpR, and WHtR.
IFG IGT
OR (95%CIs)§ AROC† OR (95%CIs)§ AROC†
Men
20-49
BMI 1.6 (1.3-2.0) 0.68 1.6 (1.3-2.1)* 0.69
WHpR 2.2 (1.7-2.9) 0.73 3.1 (2.2-4.2) 0.74
WHtR 2.0 (1.6-2.5) 0.72 2.3 (1.8-3.0) 0.73
LAP 2.0 (1.7-2.5) 0.73 2.3 (1.8-3.0) 0.75
P for trend - <0.001 - <0.001
≥ 50
BMI 1.4 (1.2-1.7) 0.65 1.5 (1.2-1.8) 0.61
WHpR 1.6 (1.3-2.0) 0.66 1.7 (1.4-2.2) 0.61
WHtR 1.6 (1.3-2.0) 0.65 1.6 (1.3-1.9) 0.61
LAP 1.4 (1.2-1.7) 0.70 2.2 (1.8-2.8) 0.66
P for trend - <0.001 - <0.001
Women
20-49
BMI 1.4 (1.3-1.6)* 0.76 1.7 (1.4-2.0)* 0.75
WHpR 1.7 (1.4-1.9)* 0.78 2.3 (1.9-2.9)* 0.78
WHtR 1.7 (1.5-1.9) 0.79 2.3 (1.9-2.7)* 0.79
LAP 2.0 (1.7-2.3) 0.81 3.2 (2.6-4.1) 0.81
P for trend - <0.001 - <0.001
≥ 50
BMI 1.1 (1.0-1.3) 0.64 1.3 (1.1-1.5)* 0.64
WHpR 1.1 (0.9-1.3)* 0.68 1.6 (1.4-2.0)* 0.66
WHtR 1.2 (1.1-1.5) 0.67 1.7 (1.4-2.0) 0.66
LAP 1.5 (1.2-1.9) 0.71 2.6 (2.1-3.4) 0.71
P for trend - <0.001 - <0.001
AROC, area under the receiver operating characteristic curve, BMI, body mass index; DM, diabetes mellitus; IFG, impaired fasting plasma 
glucose; IGT, impaired glucose tolerance; LAP, lipid accumulation product; OR, odds ratio; WHpR, waist to hip ratio; WHtR, waist to height 
ratio.
§The odds ratios (unadjusted) of incident and prevalent DM, IFG, and IGT were estimated using logistic regression analysis corresponding to 
a 1 standard deviation (log-scale) unit increment in the baseline LAP, BMI, WHpR, and WHtR.
*Paired homogeneity tests showed significant difference (P < 0.05). For paired homogeneity test LAP and one of anthropometric measures 
were fitted simultaneously in the same age- and sex-specific logistic regression model with adjustment for family history of diabetes and 
mean arterial pressure.
† The AROCs were computed for the sex- and age-specific models adjusted for mean arterial blood pressure and family history of diabetes.Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
http://www.lipidworld.com/content/9/1/45
Page 8 of 9
Conclusions
Although LAP showed some superiority over BMI in pre-
dicting FPG and 2h-PCPG and identifying prevalent dia-
betes; BMI, WHpR, WHtR, and LAP were relatively of
the same capability for predicting diabetes, with no con-
sistent superiority of one over the others across age- and
sex-groups. Although individuals with high LAP had an
increased risk of diabetes as compared with those with
low LAP, the increment in the AROC of the models
incorporating LAP over the model with BMI, WHtR, and
WHpR was negligible. Hence, it may not be plausible to
increase the resources needed for testing TGs levels.
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Table 4: Prediction of incident and prevalent DM by LAP, BMI, WHpR, and WHtR.
Prevalent DM Incident DM
OR (95%CIs)§ AROC† OR (95%CIs)§ AROC†
Men
20-49
BMI 1.3 (1.1-1.5) * 0.70 1.3 (0.9-1.8)* 0.66
WHpR 1.7 (1.4-2.1) 0.74 1.7 (1.0-2.7) 0.67
WHtR 1.5 (1.3-1.8) 0.74 1.4 (1.0-2.1) 0.66
LAP 1.4 (1.2-1.6) 0.75 1.7 (1.2-2.5) 0.71
P for trend - 0.157 - 0.051
≥ 50
BMI 1.6 (1.3-1.9) * 0.76 1.5 (1.0-2.2) 0.69
WHpR 1.6 (1.3-1.9) * 0.78 1.5 (0.9-2.4) 0.70
WHtR 1.6 (1.3-1.9) * 0.79 1.5 (1.0-2.3) 0.69
LAP 1.5 (1.3-1.8) 0.81 1.7 (1.1-2.6) 0.71
P for trend - 0.005 - 0.492
Women
20-49
BMI 1.6 (1.5-1.9)* 0.76 1.9 (1.5-2.4) 0.76
WHpR 1.8 (1.6-2.1)* 0.78 2.2 (1.7-2.9) 0.77
WHtR 1.9 (1.3-2.1)* 0.79 2.3 (1.8-3.0) 0.79
LAP 2.1 (1.8-2.5) 0.81 2.6 (1.9-3.6) 0.78
P for trend - <0.001 - 0.012
≥ 50
BMI 1.3 (1.1-1.4)* 0.65 1.5 (1.1-2.1) 0.63
WHpR 1.1 (1.0-1.3)* 0.68 1.6 (1.1-2.3) 0.64
WHtR 1.3 (1.1-1.5)* 0.68 1.9 (1.3-2.8) 0.65
LAP 1.5 (1.3-1.8) 0.72 2.1 (1.3-3.3) 0.65
P for trend - <0.001 - 0.567
AROC, area under the receiver operating characteristic curve, BMI, body mass index; DM, diabetes mellitus; IFG, impaired fasting plasma 
glucose; IGT, impaired glucose tolerance; LAP, lipid accumulation product; OR, odds ratio; WHpR, waist to hip ratio; WHtR, waist to height 
ratio.
§The odds ratios (unadjusted) of incident and prevalent DM, IFG, and IGT were estimated using logistic regression analysis corresponding to 
a 1 standard deviation (log-scale) unit increment in the baseline LAP, BMI, WHpR, and WHtR.
*Paired homogeneity tests showed significant difference (P < 0.05). For paired homogeneity test LAP and one of anthropometric measures 
were fitted simultaneously in the same age- and sex-specific logistic regression model with adjustment for family history of diabetes and 
mean arterial pressure.
† The AROCs were computed for the sex- and age-specific models adjusted for mean arterial blood pressure and family history of diabetes.Bozorgmanesh et al. Lipids in Health and Disease 2010, 9:45
http://www.lipidworld.com/content/9/1/45
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